How Has the CML Treatment Landscape Evolved Over the Past 5 Years?
Panelists discuss how chronic myeloid leukemia (CML) treatment has evolved over the past 5 years, highlighting advancements in tyrosine kinase inhibitor (TKI) therapy, improved adverse effect management, tailored treatment approaches through molecular monitoring, and increased emphasis on shared decision-making with patients.
Evolving Landscape of CML Treatment: Expert Panel Summary
This expert panel features Dr Javier Pinilla, a senior member of the Department of Malignant Hematology at Moffitt Cancer Center in Tampa, Florida, and Lauren Verity Moore, a doctorally prepared nurse practitioner specializing in hematology/oncology at Tennessee Oncology and assistant professor at Belmont University, in Nashville, Tennessee.
The discussion focuses on recent developments in CML treatment, highlighting:
- Treatment Evolution (Past 5 Years):
- TKIs remain the foundation of CML therapy.
- Newer drug formulations with improved tolerability profiles
- Enhanced ease of administration for certain TKIs
- Improved Treatment Personalization:
- More sophisticated molecular monitoring capabilities
- Greater acceptance of treatment interruptions and dose modifications
- Tailored therapeutic approaches based on individual patient factors
- Patient-Centered Care:
- Increased emphasis on shared decision-making
- Greater patient involvement in treatment planning
- Focus on improving adherence and outcomes
